{"transactions":[{"id":2564432,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":182258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\").  The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7.  Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473396},"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2564431,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":182257,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan XI L.P. (\"Canaan XI\").  The sole general partner of Canaan XI is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI.  Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473394},"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2564430,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":1333334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan XI L.P. (\"Canaan XI\").  The sole general partner of Canaan XI is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI.  Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3463201},"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2564429,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":473396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\").  The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7.  Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":473396,"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2564428,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":3936595,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan XI L.P. (\"Canaan XI\").  The sole general partner of Canaan XI is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI.  Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3936595,"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}}]}